Filing Flows › Krystal Biotech (KRYS) › Q3 2026 › vs Q3 2025
Krystal Biotech (KRYS) Q3 2026 vs Q3 2025 (year over year)
Krystal Biotech's revenue rose $29.5M (+30%) from $97.8M in Q3 2025 to $127M in Q3 2026. Operating margin 55.9% against 42.3% (+13.6 pts).
Krystal Biotech, Q3 2026: revenue $127M (+30% year over year), operating margin 55.9%, net earnings $63.1M, operating cash flow $91.2M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 55.9% | 42.3% | +13.6 pts |
| Net margin | 49.5% | 81.2% | -31.6 pts |
| Free cash flow margin | 70.9% | 38.8% | +32.1 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $127M | $97.8M | $29.5M | +30% |
| Other income, net | $9.0M | $6.6M | $2.4M | +37% |
| Operating profit | $71.1M | $41.4M | $29.8M | +72% |
| Costs & expenses | $56.2M | $56.4M | −$230K | -0.4% |
| Pre-tax earnings | $80.1M | $48.0M | $32.2M | +67% |
| Research & development | $14.9M | $14.6M | $306K | +2% |
| SG&A | $33.7M | $37.6M | −$3.8M | -10% |
| Other operating costs | $7.6M | $4.3M | $3.3M | +77% |
| Net earnings | $63.1M | $79.4M | −$16.3M | -21% |
| Income tax | $17.1M | −$31.4M | $48.5M | — |
| Depreciation | $1.5M | $1.4M | $100K | +7% |
| Share-based compensation | $13.9M | $13.2M | $786K | +6% |
| Working capital & other | $12.7M | −$54.3M | $67.0M | — |
| Operating cash flow | $91.2M | $39.7M | $51.6M | +130% |
| Free cash flow (OCF − capex) | $90.3M | $38.0M | $52.3M | +138% |
| Capital expenditures | $996K | $1.7M | −$708K | -42% |
Questions
How much did Krystal Biotech's revenue grow year over year in Q3 2026?
Krystal Biotech's revenue rose $29.5M (+30%) from $97.8M in Q3 2025 to $127M in Q3 2026. Operating margin 55.9% against 42.3% (+13.6 pts).